Ezintsha, a Sub-Division of Wits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Johannesburg, South Africa.
Department of Prevention and Community Health, Milken Institute of Public Health, George Washington University, District of Columbia, USA.
BMC Infect Dis. 2023 Jun 1;22(Suppl 1):971. doi: 10.1186/s12879-023-08324-7.
BACKGROUND: Partner-delivered HIV self-testing kits has previously been highlighted as a safe, acceptable and effective approach to reach men. However, less is known about its real-world implementation in reaching partners of people living with HIV. We evaluated programmatic implementation of partner-delivered self-testing through antenatal care (ANC) attendees and people newly diagnosed with HIV by assessing use, positivity, linkage and cost per kit distributed. METHODS: Between April 2018 and December 2019, antenatal care (ANC) clinic attendees and people or those newly diagnosed with HIV clients across twelve clinics in three cities in South Africa were given HIVST kits (OraQuick Rapid HIV-1/2 Antibody Test, OraSure Technologies) to distribute to their sexual partners. A follow-up telephonic survey was administered to all prior consenting clients who were successfully reached by telephone to assess primary outcomes. Incremental economic costs of the implementation were estimated from the provider's perspective. RESULTS: Fourteen thousand four hundred seventy-three HIVST kits were distributed - 10,319 (71%) to ANC clients for their male partner and 29% to people newly diagnosed with HIV for their partners. Of the 4,235 ANC clients successfully followed-up, 82.1% (3,475) reportedly offered HIVST kits to their male partner with 98.1% (3,409) accepting and 97.6% (3,328) using the kit. Among ANC partners self-testing, 159 (4.8%) reported reactive HIVST results, of which 127 (79.9%) received further testing; 116 (91.3%) were diagnosed with HIV and 114 (98.3%) initiated antiretroviral therapy (ART). Of the 1,649 people newly diagnosed with HIV successfully followed-up; 1,312 (79.6%) reportedly offered HIVST kits to their partners with 95.8% (1,257) of the partners accepting and 95.9% (1,206) reported that their partners used the kit. Among these index partners, 297 (24.6%) reported reactive HIVST results of which 261 (87.9%) received further testing; 260 (99.6%) were diagnosed with HIV and 258 (99.2%) initiated ART. The average cost per HIVST distributed in the three cities was US$7.90, US$11.98, and US$14.81, respectively. CONCLUSIONS: Partner-delivered HIVST in real world implementation was able to affordably reach many male partners of ANC attendees and index partners of people newly diagnosed with HIV in South Africa. Given recent COVID-19 related restrictions, partner-delivered HIVST provides an important strategy to maintain essential testing services.
背景:伴侣提供 HIV 自检包已被强调为一种安全、可接受和有效的方法,可用于接触男性。然而,对于伴侣提供 HIV 自检包在接触 HIV 感染者的伴侣方面的实际实施情况,我们知之甚少。我们通过评估使用情况、阳性率、关联性和每包分发的成本,评估了通过产前护理 (ANC) 就诊者和新诊断出 HIV 的人群实施伴侣提供的自我检测的方案实施情况。
方法:2018 年 4 月至 2019 年 12 月,南非三个城市的 12 个诊所的 ANC 就诊者和新诊断出 HIV 的患者或客户被给予 HIVST 试剂盒(OraQuick 快速 HIV-1/2 抗体检测试剂盒,OraSure 技术),以分发给他们的性伴侣。对所有成功通过电话联系到的事先同意的客户进行了后续电话调查,以评估主要结果。从提供者的角度估计了实施的增量经济成本。
结果:共分发了 14473 个 HIVST 试剂盒-10319 个(71%)给 ANC 就诊者,用于他们的男性伴侣,29%给新诊断出 HIV 的人,用于他们的伴侣。在成功随访的 4235 名 ANC 就诊者中,据报道,82.1%(3475 人)向他们的男性伴侣提供了 HIVST 试剂盒,98.1%(3409 人)接受了试剂盒,97.6%(3328 人)使用了试剂盒。在 ANC 伴侣自检中,159 人(4.8%)报告了 HIVST 检测结果阳性,其中 127 人(79.9%)接受了进一步检测;116 人(91.3%)被诊断为 HIV,114 人(98.3%)开始接受抗逆转录病毒治疗(ART)。在 1649 名新诊断出 HIV 的人成功随访中,据报道,1312 人(79.6%)向他们的伴侣提供了 HIVST 试剂盒,其中 95.8%(1257 人)的伴侣接受了试剂盒,95.9%(1206 人)报告说他们的伴侣使用了试剂盒。在这些指数伴侣中,297 人(24.6%)报告了 HIVST 检测结果阳性,其中 261 人(87.9%)接受了进一步检测;260 人(99.6%)被诊断为 HIV,258 人(99.2%)开始接受 ART。在这三个城市,每包 HIVST 的平均分发成本分别为 7.90 美元、11.98 美元和 14.81 美元。
结论:在现实世界中实施的伴侣提供的 HIV 自检包能够负担得起地接触到南非 ANC 就诊者的许多男性伴侣和新诊断出 HIV 的人的指数伴侣。鉴于最近与 COVID-19 相关的限制,伴侣提供的 HIV 自检提供了维持基本检测服务的重要策略。
BMC Infect Dis. 2024-2-29
BMC Infect Dis. 2025-7-21
BMC Public Health. 2020-1-15